



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/672,077 Confirmation No.: 4735
Applicant : Linda ARTERBURN et al.
Filed : September 29, 2003
Title : GLYCEMIC CONTROL FOR PREDIABETES AND/OR
DIABETES TYPE II USING DOCOSAHEXAENOIC
TC/Art Unit : 1614
Examiner: : Unassigned

Docket No. : 62611.000235
Customer No. : 21967

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.


In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: April 29, 2004

By:



Jeffrey T. Perez
Registration No. 52,110

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

JTP/sdw

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/672,077
Filing Date	September 29, 2003
First Named Inventor	Linda ARTERBURN et al.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	62611.000235

Sheet 1 of 3

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 5034415	07-23-1991	Rubin	
	2.	US- 6069168	05-30-2000	Horrobin et al.	
	3.	US- 6365628	04-02-2002	Berge	

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	4.	EP	0 302 481 A2	02-08-1989	Rubin		<input type="checkbox"/>	<input type="checkbox"/>
	5.	EP	0 843 972 A1	05-27-1998	Klör et al.		<input type="checkbox"/>	<input type="checkbox"/>
	6.	WO	01/68582 A1	09-20-2001	Berge et al.,		<input type="checkbox"/>	<input type="checkbox"/>
	7.	WO	02/11564 A2	02-14-2002	Bell et al.		<input type="checkbox"/>	<input type="checkbox"/>
	8.	WO	02/11550 A2	02-14-2002	Koike et al.		<input type="checkbox"/>	<input type="checkbox"/>
	9.	EP	0 843 972 B1	07-31-2002	Klör et al.		<input type="checkbox"/>	<input type="checkbox"/>
	10.	WO	01/60778 A2	08-23-2001	Serhan et al.		<input type="checkbox"/>	<input type="checkbox"/>

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	11.	Y. M. DENKINS, Omega-3 PUFA Supplementation and Insulin Sensitivity, Experimental Biology, April 20-24, 2002, 1 page		
	12.	NADIR SALEEM DAWOOD et al., Maximum Number of Oral Hypoglycemic Agents in the Treatment of Type 2 Diabetes, printed 8/22/2002 < http://www.medscape.com/viewarticle/439539?mpid=2529 >, pp. 1-2		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Application Number****10/672,077****Filing Date****September 29, 2003****First Named Inventor****Linda ARTERBURN et al.****Art Unit****1614****Examiner Name****Unassigned****Sheet****2****of****3****Attorney Docket Number****62611.000235****NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	13.	GERALD REAVEN, MD, Metabolic Syndrome, Pathophysiology and Implications for Management of Cardiovascular Disease, Clinician Update, pp. 286-288, July 16, 2002		
	14.	FASCHING P. et al., Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance, Diabetes 1991 May; 40(5):583-9, printed 8/7/2002, < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PubMed&list_uids=20223 >, (1 page Abstract)		
	15.	FRIEDBERG C. E. et al., Fish oil and glycemic control in diabetes. A meta-analysis, Diabetes Care 1998, April 21 (4):494-500, < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=95713 > printed 8/6/2002 (1 page Abstract)		
	16.	MICHAEL J. DAVIES et al., Effects of Moderate Alcohol Intake on Fasting Insulin and Glucose Concentrations and Insulin Sensitivity in Postmenopausal Women, A Randomized Controlled Trial, Vol. 287, No. 19, May 15, 2002, JAMA Clinical Investigation, < http://jama.ama-assn.org/issues/v287n19/abs/jci20001.html >, printed 7/22/2002 (Abstract)		
	17.	SHIMURA T. et al., Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM), Biol. Pharm Bull 1997, May 20 (5):507-10 (Abstract), printed 8/6/2002, < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=91789 > (1 page Abstract)		
	18.	JENNIFER B. MARKS, The Insulin Resistance Syndrome, < http://www.woundcare.org/newsvol1n3/ar1.htm >, printed 7/22/2002, pp. 1-3		
	19.	CONSUELO HUERTA et al., Risk of Acute Liver Injury in Patients With Diabetes, Medscape Abstract printed 10-17-2002, < http://www.medscape.com/viewarticle/441918_print >, pp. 1-7		
	20.	A. MICHAEL LINCOFF et al., Diabetes and Cardiovascular Disease: The Role of the Glycoprotein IIb/IIIa Inhibitors, Medscape Abstract, < http://medscape.com/viewprogram/1944?mpid=1969 >, printed 8/12/2002, 44 pages		

EXAMINER SIGNATURE**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Application Number****10/672,077****Filing Date****September 29, 2003****First Named Inventor****Linda ARTERBURN et al.****Art Unit****1614****Examiner Name****Unassigned****Sheet****3****of****3****Attorney Docket Number****62611.000235****NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	21.	YVONNE M. DENKINS et al., Docosahexaenoic Acid (DHA) Supplementation and Insulin Sensitivity: A Pilot Study, ADA - Annual Meeting Abstract, printed 6/14/2002, 1 page		
	22.	PAOLO RUBBA et al., N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?, Eur. J. Lipid Sci. Technol. 103 (2001), 407-418		
	23.	LLOYD A. HORROCKS et al., Health Benefits of Docosahexaenoic Acid (DHA), Pharmacological Research, Vol. 40, No. 3, 1999, pp. 211-225		
	24.	DILYS J. FREEMAN et al., C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study, Diabetes, Vol. 51, May 2002, pp. 1596-1600		

EXAMINER SIGNATURE**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.